Solaymani-Dodaran M, Logan R F A, West J, Card T, Coupland C
University of Nottingham, Division of Epidemiology and Public Health, Queen's Medical Centre, Nottingham NG7 2UH, UK.
Gut. 2004 Aug;53(8):1070-4. doi: 10.1136/gut.2003.028076.
BACKGROUND AND AIMS: While patients with Barrett's oesophagus develop oesophageal adenocarcinoma more frequently than the general population, it has controversially been suggested that gastro-oesophageal reflux (GORD) itself is a more important determinant of risk. In order to assess the validity of this suggestion, we examined the risk of oesophageal cancer in patients with Barrett's and with GORD compared with the general population in a community based cohort study. METHODS: Cohorts of patients with Barrett's (n = 1677), oesophagitis (n = 6392), and simple reflux (n = 6328), and a reference cohort (n = 13416) were selected from the General Practice Research Database. The last three cohorts were matched to the Barrett's cohort by general practitioner practice, age, and sex. Cox's regression analysis was used to calculate relative risks for oesophageal cancer. Standardised incidence ratio methodology was used to estimate the relative risks for oesophageal adenocarcinoma. RESULTS: A total of 137 oesophageal cancers were identified, of which 94 prevalent cases were excluded. The hazard ratios for oesophageal cancer were 10.6 (5.1-22.0), 2.2 (0.9-5.2), and 1.7 (0.7-4.5) in the Barrett's, oesophagitis, and reflux cohorts compared with the reference cohort, respectively. The corresponding relative risks for oesophageal adenocarcinoma were 29.8 (9.6-106), 4.5 (1.04-19.6), and 3.1 (0.6-14.2). CONCLUSION: Barrett's oesophagus increases the risk of oesophageal cancer approximately 10 times and oesophageal adenocarcinoma approximately 30 times compared with the general population. There is only a modestly increased risk of oesophageal cancer in patients with reflux who have no record of Barrett's oesophagus. Our findings therefore do not support the suggestion that gastro-oesophageal reflux disease itself predisposes to cancer.
背景与目的:虽然巴雷特食管患者发生食管腺癌的频率高于普通人群,但有争议地认为胃食管反流(GORD)本身是更重要的风险决定因素。为了评估这一观点的正确性,我们在一项基于社区的队列研究中,比较了巴雷特食管患者、胃食管反流患者与普通人群患食管癌的风险。 方法:从全科医疗研究数据库中选取了巴雷特食管患者队列(n = 1677)、食管炎患者队列(n = 6392)和单纯反流患者队列(n = 6328),以及一个对照队列(n = 13416)。后三个队列根据全科医生诊所、年龄和性别与巴雷特食管患者队列进行匹配。采用Cox回归分析计算食管癌的相对风险。使用标准化发病率比方法估计食管腺癌的相对风险。 结果:共识别出137例食管癌患者,其中94例现患病例被排除。与对照队列相比,巴雷特食管、食管炎和反流队列中食管癌的风险比分别为10.6(5.1 - 22.0)、2.2(0.9 - 5.2)和1.7(0.7 - 4.5)。食管腺癌的相应相对风险分别为29.8(9.6 - 106)、4.5(1.04 - 19.6)和3.1(0.6 - 14.2)。 结论:与普通人群相比,巴雷特食管使患食管癌的风险增加约10倍,患食管腺癌的风险增加约30倍。在没有巴雷特食管记录的反流患者中,患食管癌的风险仅适度增加。因此,我们的研究结果不支持胃食管反流病本身易患癌症的观点。
Scand J Gastroenterol. 2004-7
Aliment Pharmacol Ther. 2006-1-15
J Gastroenterol Hepatol. 2025-7
BMC Gastroenterol. 2024-2-5
Int J Mol Sci. 2023-4-25
World J Gastroenterol. 2022-3-28
Cancers (Basel). 2022-1-20
Genes (Basel). 2021-10-10
Cancer Immunol Immunother. 2022-4
Pharmacoepidemiol Drug Saf. 2002
Gastroenterology. 2000-8
QJM. 2000-6